Investment Rating - The report assigns a "Recommended" rating to the company, indicating an expected price increase of over 15% relative to the benchmark index within the next 12 months [3][11]. Core Insights - The company is undergoing a strategic acquisition to enhance its technology matrix, which is expected to lead to a clear trend of reduced losses and improved operational margins [8]. - The acquisition involves the purchase of 100% equity in two companies for a total consideration of approximately 365.7 million yuan, along with additional capital increases [8]. - The company anticipates a significant narrowing of losses, with projected net losses for 2025 expected to decrease by 54.56% to 63.22% year-on-year [8]. Financial Forecasts - Projected revenue for 2024 is 3,013 million yuan, with a growth rate of 3.5%. Revenue is expected to decline to 2,716 million yuan in 2025, followed by increases to 3,209 million yuan in 2026 and 3,717 million yuan in 2027 [2][9]. - The net profit attributable to shareholders is forecasted to be -601 million yuan in 2024, improving to -242 million yuan in 2025, and turning positive with 21 million yuan in 2026 and 162 million yuan in 2027 [2][9]. - Earnings per share (EPS) is projected to be -1.44 yuan in 2024, -0.58 yuan in 2025, 0.05 yuan in 2026, and 0.39 yuan in 2027 [2][9]. Valuation Metrics - The price-to-sales (P/S) ratio is expected to be 9.2 in 2024, 10.2 in 2025, 8.6 in 2026, and 7.4 in 2027 [2][9]. - The price-to-earnings (P/E) ratio is not applicable for 2024 and 2025, but is projected to be 1312 in 2026 and 170 in 2027 [2][9].

Group 1 - The company will hold its first extraordinary general meeting of 2026 on March 3, 2026, at 15:00 [2][6] - Voting will be conducted through both on-site and online methods, utilizing the Shanghai Stock Exchange's network voting system [2][4] - The voting period for online participation will be from 9:15 to 15:00 on the day of the meeting [1][2] Group 2 - Shareholders must register to attend the meeting, with registration available from February 26, 2026, from 9:30 to 17:00 [8][9] - Natural person shareholders must present valid identification and proof of shareholding, while corporate shareholders must provide additional documentation [7][9] - Proxy representation is allowed, but the proxy must also present valid identification and authorization documents [7][9] Group 3 - The meeting will include specific resolutions that require separate voting for small and medium investors [2][3] - Certain shareholders with related party transactions must abstain from voting on specific resolutions [3] - All shareholders must complete voting on all resolutions before submission [5]

Meeting Information - The first extraordinary general meeting of 2026 will be held on March 3, 2026, at 15:00 [1] - The meeting will take place at the International Conference Center, Huada Space Center, Shenzhen [1] - Voting will be conducted through the Shanghai Stock Exchange's online voting system, available from 9:15 to 15:00 on the day of the meeting [1][4] Voting Procedures - Shareholders can vote via the Shanghai Stock Exchange's online voting system or in person [6] - Specific procedures for margin trading, transfer, and other related accounts must comply with relevant regulations [2] - Shareholders holding multiple accounts can aggregate their voting rights across all accounts [6] Meeting Agenda - The meeting will review proposals that were approved by the board on January 31, 2026, with details disclosed on February 2, 2026 [3] - There are no special resolutions or proposals involving preferred shareholders [5] Attendance Requirements - Shareholders registered by the close of trading on the day before the meeting are eligible to attend [8] - Both individual and corporate shareholders must present valid identification and proof of shareholding [10] Registration Details - Registration for the meeting will occur on February 26, 2026, from 9:30 to 17:00 [9] - Shareholders can register via mail or in person, with specific documentation required [10] Additional Information - Attendees are responsible for their own travel and accommodation expenses [12] - It is advised that attendees arrive at least 30 minutes early for check-in [13]

证券代码：688114 证券简称：华大智造 公告编号：2026-006 深圳华大智造科技股份有限公司 关于召开2026年第一次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东会类型和届次：2026年第一次临时股东会 （二） 股东会召集人：董事会 召开地点：深圳市盐田区梅沙街道云华路 9 号华大时空中心 C 区国际会议 中心 419 会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2026 年 3 月 3 日 至2026 年 3 月 3 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 1 股东会召开日期：2026年3月3日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 （三） 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相 结合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2026 年 3 月 3 日 15 点 0 ...

中新网武汉2月5日电 (卢琪 刘展)2025光谷青桐汇Ultra年汇4日在武汉东湖高新区(又称"中国光谷")举 行，武汉创新创业标杆品牌"光谷青桐汇"的首个实体化运营基地——"青桐之家"启动运营，18个青桐汇 项目集中签约。 融资成果签约环节。 主办方供图 "光谷青桐汇升级和'青桐之家'落地，是光谷构建热带雨林式创新生态的关键一步。"东湖高新区科创局 局长龚学艺表示，2026年光谷青桐汇将深耕未来产业，聚焦人工智能、人形机器人、脑机接口、量子科 技、6G通信、先进半导体等10个赛道，支持硬科技创业孵化，培育一流科创企业家。据了解，光谷青 桐汇运行12年，已对接、支持科创企业超1300家，涌现出华大智造、旷视科技、禾赛科技等诸多企业。 当日，光谷青桐汇2025年度十大项目进行路演，涵盖大模型、薄膜铌酸锂光子芯片、AI光学检测、智 能遥感卫星等前沿领域，并为科创企业、投资机构颁发"青桐·创新领航奖""青桐·硬核攻坚奖""年度贡献 机构"等奖项。(完) 图为"青桐 之家"启动运营环节。 主办方供图 据介绍，"青桐之家"将为创业者提供集办公、路演、展示于一体的空间，并构建从概念验证到产业协同 的创业生态。其中，在资源 ...

Core Viewpoint - The company is acquiring 100% equity of two subsidiaries, Shijian Qihua and Huada Xifeng, for a total price of 365.7 million yuan, aiming to integrate cutting-edge technologies in spatial genomics and nanopore sequencing [1] Group 1: Acquisition Details - The acquisition involves cash payments of 158 million yuan for Shijian Qihua and 207.7 million yuan for Huada Xifeng, with additional investments of 70 million yuan and 60 million yuan respectively to support their business development [2] - The company will also provide a loan of 7 million yuan to Huada Xifeng at an interest rate of 2.5% for three years to assist with repayments and daily operations [2] Group 2: Financial Projections - Both Shijian Qihua and Huada Xifeng are currently unprofitable, but are expected to achieve profitability by 2026 and 2028 respectively, with cumulative profit targets of at least 5.01 million yuan and 8.28 million yuan [3] - If the profit commitments are not met, Huada Technology will provide cash compensation, and any impairment beyond the cumulative compensation will also be compensated [3] Group 3: Strategic Integration - The integration of Shijian Qihua and Huada Xifeng is expected to enhance the company's technological ecosystem, creating a complete technical matrix for sequencing products [3] - The companies share a strong alignment in upstream suppliers and downstream customer bases, which is anticipated to facilitate rapid integration and collaboration post-acquisition [4] Group 4: Revenue Forecast - The company forecasts revenues of 2.918 billion yuan, 3.383 billion yuan, and 3.972 billion yuan for 2025-2027, with year-on-year growth rates of -3.15%, 15.94%, and 17.43% respectively [4] - The projected net profit for the same period is -233 million yuan, -11 million yuan, and 102 million yuan, with significant year-on-year growth rates of 61.20%, 95.42%, and 1052.54% [4]

Core Viewpoint - BGI Genomics plans to enhance its technology matrix through the acquisition of assets, aiming to solidify its position as a leading manufacturer in the life sciences sector by integrating cutting-edge technologies [1][4]. Group 1: Acquisition Details - BGI Genomics intends to acquire 100% equity of Sanjian Qifa and BGI Xifeng for a total cash consideration of 366 million yuan, which will incorporate two core technologies: spatial genomics and nanopore sequencing [2]. - The acquisition will enable BGI Genomics to establish a comprehensive technology ecosystem covering short-read, long-read, and spatial genomics, facilitating a one-stop service from library construction to sequencing and data analysis [2]. - The counterparties of the transaction have provided clear performance commitments, with Sanjian Qifa promising a cumulative net profit of no less than 50.1 million yuan from 2026 to 2028, and BGI Xifeng committing to a cumulative net profit of no less than 82.8 million yuan from 2028 to 2030 [2]. Group 2: Strategic Significance - The acquisition is expected to significantly reduce related-party transactions and resolve potential competition issues in the nanopore sequencing business, thereby enhancing the company's sustainable operational capabilities [2]. - Post-acquisition, BGI Genomics will achieve resource sharing and synergy in supply chain procurement, technology development, and customer service, which will serve as important growth engines for the company [2]. Group 3: Market Position and Performance - BGI Genomics has shown a notable improvement in its operational fundamentals, with a projected net loss of 221 million to 273 million yuan for 2025, representing a reduction in losses by approximately 60% compared to the previous year [3]. - The company secured 61% of the domestic high-throughput sequencing instrument market in 2025, with 232 units won in bids, demonstrating strong market penetration and customer recognition [3]. - BGI Genomics has been proactive in the AI pathology field since 2019, establishing the Spatial Pathology Alliance in 2025 and successfully registering its self-developed PMIF-20 pathology slide staining scanner, reinforcing its foundation for integrating AI with pathology analysis [3].

Core Viewpoint - BGI Genomics (688114) plans to acquire 100% equity of two companies, Shenzhen BGI Sanjian Qifa Technology Co., Ltd. and Hangzhou BGI Xufeng Technology Co., Ltd., for a total of 366 million yuan, integrating cutting-edge technologies in spatial omics and nanopore sequencing into its business [1][3]. Group 1: Acquisition Details - The total acquisition price is 366 million yuan, with BGI Sanjian Qifa valued at 158 million yuan and BGI Xufeng at 208 million yuan [3]. - BGI Genomics will also inject 70 million yuan and 60 million yuan into BGI Sanjian Qifa and BGI Xufeng, respectively, to support their operations and business expansion [3][4]. - A loan of 70 million yuan will be provided to BGI Xufeng at an interest rate of 2.5% for three years to repay debts [3]. Group 2: Financial Performance - Both target companies are currently in a high-investment R&D phase and have not yet achieved profitability. BGI Sanjian Qifa reported revenues of 60.74 million yuan and 27.99 million yuan for 2024 and January-October 2025, respectively, with net losses of 11.71 million yuan and 44.98 million yuan [5]. - BGI Xufeng's revenues were 44.02 million yuan and 66.14 million yuan for the same periods, with net losses of 70.66 million yuan and 85.01 million yuan [5]. Group 3: Strategic Implications - The acquisition will enable BGI Genomics to create a comprehensive technology chain covering short-read, long-read, and spatial omics technologies, positioning it uniquely in the global market [5][6]. - The integration of these technologies is expected to enhance the company's competitive edge and profitability in the long term, with BGI Xufeng and BGI Sanjian Qifa projected to achieve profitability by 2026 and 2028, respectively [6][7]. Group 4: Valuation and Market Reaction - The valuation of BGI Sanjian Qifa shows a high appreciation rate of 2460.66%, while BGI Xufeng has a valuation increase of 296.55% [8]. - The acquisition pricing is considered reasonable compared to industry standards, with dynamic price-to-sales ratios around 3 times, significantly lower than comparable companies in their respective fields [9]. Group 5: Performance Commitments - Performance commitments have been established, with BGI Sanjian Qifa expected to achieve net profits of no less than 5 million yuan, 18.7 million yuan, and 26.4 million yuan from 2026 to 2028, totaling at least 50.1 million yuan [9]. - BGI Xufeng is expected to achieve net profits of no less than 5.2 million yuan, 24.6 million yuan, and 53 million yuan from 2028 to 2030, totaling at least 82.8 million yuan [9].

Core Viewpoint - BGI Genomics is making a significant move by acquiring 100% equity of two subsidiaries, Shenzhen Huada Sanjian Qifa Technology Co., Ltd. and Hangzhou Huada Xufeng Technology Co., Ltd., for a total of 366 million yuan, integrating cutting-edge technologies in spatial omics and nanopore sequencing into its operations [1][3]. Group 1: Acquisition Details - The total acquisition price is 366 million yuan, with Shenzhen Huada Sanjian Qifa valued at 158 million yuan and Hangzhou Huada Xufeng at 208 million yuan [3]. - BGI Genomics plans to inject 70 million yuan and 60 million yuan into the respective companies for operational expansion and working capital [3]. - A loan of 70 million yuan will be provided to Hangzhou Huada Xufeng at a 2.5% interest rate for three years to repay existing debts [3]. Group 2: Financial Performance - Both acquired companies are currently in a high-investment R&D phase and have not yet achieved profitability, with significant losses reported [5][7]. - Financial data shows that Shenzhen Huada Sanjian Qifa had revenues of 60.74 million yuan and 27.99 million yuan for 2024 and the first ten months of 2025, respectively, with net losses of 11.71 million yuan and 44.98 million yuan [7]. - Hangzhou Huada Xufeng reported revenues of 44.02 million yuan and 66.14 million yuan for the same periods, with net losses of 70.66 million yuan and 85.01 million yuan [7]. Group 3: Strategic Implications - The acquisition aims to create a comprehensive technology chain that includes short-read, long-read, and spatial omics technologies, positioning BGI Genomics as a unique player in the global market [6][8]. - The integration of these technologies is expected to enhance customer service capabilities and meet diverse research needs [8]. - The companies are projected to achieve profitability by 2026 and 2028, respectively, with specific profit commitments outlined [10]. Group 4: Valuation and Market Perception - The valuation of the acquired companies shows a high appreciation rate, with Shenzhen Huada Sanjian Qifa at 2460.66% and Hangzhou Huada Xufeng at 296.55% [9]. - The rationale behind the high valuation is attributed to the companies' technological advantages and potential strategic value in the market [9]. - The acquisition is viewed as a cost-effective move for BGI Genomics, aligning with industry standards and providing a competitive edge [9].

Core Viewpoint - The company Huada Zhi Zao (688114) has announced a plan to acquire "San Jian Qi Fa" and "Hua Da Xu Feng" for 366 million yuan, aiming to integrate spatial omics and nanopore sequencing technologies, positioning itself as the only life science company globally with a complete product matrix of "long-read sequencing + spatial omics" [1][7]. Group 1: Nanopore Sequencing Business - The Cyclone SEQ series has shown significant market expansion since its launch in September 2024, with a diverse customer base including universities, research institutes, and hospitals, and has successfully entered overseas markets in Asia-Pacific and Latin America [1][7]. - The nanopore sequencing business is expected to grow due to market space and synergy effects, with a projected global compound annual growth rate of approximately 22% for long-read sequencing [2][8]. - The company plans to enhance its market competitiveness through channel integration and cost optimization, leveraging its established global sales network and reducing unit costs via large-scale production [2][8]. Group 2: Spatial Omics Business - The spatial omics technology has accumulated over 200 clients, with about half from industrial sectors and the rest from academic and research institutions, indicating a high customer repurchase rate that reflects its practical value [3][9]. - The company has implemented a differentiated global strategy for spatial omics, focusing on local service capabilities in China, targeting top academic institutions in the Americas, and establishing a balanced cooperation network in Europe [4][10]. - The core competitive advantage of spatial omics lies in its ability to achieve high resolution and large field of view, addressing industry challenges and providing critical support for detailed research in tumor microenvironments and cellular interactions [5][11]. Group 3: Future Growth Directions - The company aims to expand its application boundaries in the research field, exploring potential uses in neuroscience, brain-machine interfaces, embryonic development, agricultural breeding, and forensic testing [6][12]. - In the clinical field, the company is collaborating with global pharmaceutical companies and hospital experts to advance digital spatial pathology analysis, fostering rapid implementation and industrial application of this leading technology [6][12]. - The company plans to enhance customer engagement by offering bundled solutions that integrate nanopore technology with single-cell sequencing and spatial omics, optimizing pricing strategies to attract a broader user base [3][9].